Detalhe da pesquisa
1.
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
Acta Oncol
; 61(5): 619-624, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139727
2.
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Cancer
; 122(19): 2961-70, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27315546
3.
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.
Clin Cancer Res
; 28(5): 960-971, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965952
4.
Elastosis in ERα-positive male breast cancer.
Virchows Arch
; 478(2): 257-263, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929565
5.
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).
Breast Care (Basel)
; 16(6): 598-606, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35087363
6.
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
J Natl Cancer Inst
; 110(1)2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28922787
7.
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Eur J Cancer
; 51(12): 1497-510, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26025767